Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

59.28 +0.34 (+0.59%)
Streaming Delayed Price Updated: 3:31 PM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
67 68 Next >
News headline image
MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough
The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the... 
Via MarketMinute
Topics Intellectual Property
News headline image
Firing on All Cylinders: Eli Lilly (NYSE:LLY) Q4 Earnings Lead the Way
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Eli Lilly (NYSE:L... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Why Bristol-Myers Squibb (BMY) Stock Is Up Today
What Happened? Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 2.6% in the afternoon session after its positive momentum continued... 
Via StockStory
Topics Artificial Intelligence
Bristol-Myers Squibb Co. (NYSE:BMY): A High-Yield Dividend Stock for Income Investors ↗
Via Chartmill
News headline image
Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience
As of March 25, 2026, Merck & Co., Inc. (NYSE: MRK) stands at a pivotal crossroads in its 135-year history. Known globally as a titan of oncology and vaccines, the Rahway, New Jersey-based... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
What Is Considered a Good Stock Dividend? 2 Healthcare Stocks Fit the Bill. ↗
This pair busts the myth of the sector being a desert for income investors. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol-Myers Squibb Shares Jump 3.3% on Robust 2026 Guidance and High Dividend Yield
Shares of pharmaceutical giant Bristol-Myers Squibb (NYSE:BMY) climbed 3.3% in early trading on Monday, March 23, 2026, after the company issued a surprisingly robust financial outlook for the fiscal... 
Via MarketMinute
Topics Economy Initial Public Offering Intellectual Property
News headline image
Should You Buy Bristol Myers Squibb Stock for Its 4.4%-Yielding Dividend? ↗
The healthcare company has been a top dividend growth stock for years. 
Via The Motley Fool
Topics Intellectual Property
News headline image
FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market
In a landmark decision for the dermatology sector, the U.S. Food and Drug Administration (FDA) has officially approved ICOTYDE™ (icotrokinra), a first-of-its-kind oral peptide for the treatment of... 
Via MarketMinute
News headline image
1 High-Yield Dividend Stock That's Too Cheap to Ignore ↗
Sometimes "boring" is the way to go. 
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
AbbVie Shares Retreat to Multi-Month Lows Amid Competitive Headwinds and Technical Breakdown
The pharmaceutical giant AbbVie (NYSE: ABBV) experienced a sharp decline on Wednesday, March 18, 2026, as its stock price tumbled to its lowest level since mid-2025. Shares of the Illinois-based... 
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
Bristol‑Myers Squibb: The Boring Dividend Stock I'd Happily Hold Through Any Crash ↗
This pharma stock should hold up well if the market tanks. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
READYSTATE Dumps 361,000 Workiva Shares Worth $32 Million ↗
This technology firm provides cloud-based compliance and reporting solutions for organizations with complex regulatory needs worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Grand Divergence: Finance Surges as Health Care Braces for a Historic Q1 Earnings Slump
As the first quarter of 2026 draws to a close, the S&P 500 is witnessing one of the most dramatic sector performance splits in recent financial history. According to consensus estimates as of March 17,... 
Via MarketMinute
Topics Earnings Economy Initial Public Offering
News headline image
Merck & Co. Trades Ex-Dividend as Healthcare Emerges as a Volatility Hedge in 2026
Amidst a backdrop of mounting geopolitical tensions and sharp swings in the broader indices, pharmaceutical giant Merck & Co. (NYSE: MRK) officially trades ex-dividend today, March 16, 2026. Investors... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
1 ETF That Could Turn $100 Per Month Into $67,380 ↗
How does solid growth -- plus a 3.3% dividend yield sound? 
Via The Motley Fool
Topics ETFs Economy World Trade
News headline image
1 S&P 500 Stock Worth Your Attention and 2 We Question
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch... 
Via StockStory
Topics Stocks
News headline image
BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier
In a watershed moment for the biotechnology sector, BioNTech SE (NASDAQ: BNTX) has reported its full-year 2025 financial results, signaling the definitive end of the COVID-19 vaccine gold rush and the... 
Via MarketMinute
News headline image
3 Healthcare Stocks Paying the Highest Dividends of 2026 ↗
A handful of the industry's income-generating gems are hiding in plain sight. 
Via The Motley Fool
News headline image
Why Bristol Myers Squibb Stock Crushed it in February ↗
It delivered for shareholders in its fourth quarter of 2025 with a double beat on analyst projections. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Top Healthcare Dividend Stocks to Buy and Hold Forever ↗
These stocks can be slow-and-steady wealth compounders. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Q4 Earnings Outperformers: Bristol-Myers Squibb (NYSE:BMY) And The Rest Of The Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗
The founder criticized traditional chemotherapy approaches from Amgen and Bristol Myers and hyped up the mechanism behind Anktiva. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
How to Spot Winning Innovation ↗
Author Lorraine Marchand stops by to chat. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
FourWorld Takes a Major Swing on Sable Offshore (SOC), Buying 8 Million Shares ↗
Specializing in offshore oil and gas, Sable Offshore Corp. operates three platforms and an onshore facility across 16 federal leases. 
Via The Motley Fool
Topics Energy Lawsuit
News headline image
Big Pharma Dividend Stock BMY Could Help Turn $100,000 Into a Seven‑Figure Retirement ↗
Bristol Myers Squibb has an attractive 4% yield and a strong dividend history. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy
In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total... 
Via MarketMinute
Topics Intellectual Property
News headline image
3 Reasons to Avoid BMY and 1 Stock to Buy Instead
Over the past six months, Bristol-Myers Squibb has been a great trade, beating the S&P 500 by 22.8%. Its stock price has climbed to $61.33, representing a healthy 30.1% increase. This was partly due to... 
Via StockStory
Topics Stocks
News headline image
European Commission Grants Marketing Authorization to Cytokinetics for Cardiac Drug MYQORZO
In a landmark decision for the cardiovascular treatment landscape, the European Commission (EC) officially granted marketing authorization to Cytokinetics, Inc. (Nasdaq: CYTK) on February 17, 2026, for... 
Via MarketMinute
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.